These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36305696)

  • 41. Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.
    Stauffer VL; Sniadecki JL; Piezer KW; Gatz J; Kollack-Walker S; Hoffmann VP; Conley R; Durell T
    BMC Psychiatry; 2010 Nov; 10():89. PubMed ID: 21047395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
    Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
    Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates.
    Cunningham JI; Eyerman DJ; Todtenkopf MS; Dean RL; Deaver DR; Sanchez C; Namchuk M
    J Psychopharmacol; 2019 Oct; 33(10):1303-1316. PubMed ID: 31294646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.
    Newcomer JW; Campos JA; Marcus RN; Breder C; Berman RM; Kerselaers W; L'italien GJ; Nys M; Carson WH; McQuade RD
    J Clin Psychiatry; 2008 Jul; 69(7):1046-56. PubMed ID: 18605811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.
    Moteshafi H; Zhornitsky S; Brunelle S; Stip E
    Drug Saf; 2012 Oct; 35(10):819-36. PubMed ID: 22967188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet.
    Sun L; Yagoda S; Du Y; von Moltke L
    Drug Des Devel Ther; 2019; 13():2941-2955. PubMed ID: 31686778
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.
    Citrome L; Holt RI; Walker DJ; Hoffmann VP
    Clin Drug Investig; 2011; 31(7):455-82. PubMed ID: 21495734
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of naltrexone on body fat mass in olanzapine-treated schizophrenic or schizoaffective patients: a randomized double-blind placebo-controlled pilot study.
    Taveira TH; Wu WC; Tschibelu E; Borsook D; Simonson DC; Yamamoto R; Langleben DD; Swift R; Elman I
    J Psychopharmacol; 2014 Apr; 28(4):395-400. PubMed ID: 24218048
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
    L'Italien GJ; Casey DE; Kan HJ; Carson WH; Marcus RN
    J Clin Psychiatry; 2007 Oct; 68(10):1510-6. PubMed ID: 17960964
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.
    Citrome L; O'Malley SS; McDonnell D; Jiang Y; Simmons AC; Berry MP; Dipetrillo LE
    Innov Clin Neurosci; 2019 May; 16(5-6):15-21. PubMed ID: 31440397
    [No Abstract]   [Full Text] [Related]  

  • 51. Effect of olanzapine, risperidone, and haloperidol treatment on weight and body mass index in first-episode schizophrenia patients in India: a randomized, double-blind, controlled, prospective study.
    Saddichha S; Manjunatha N; Ameen S; Akhtar S
    J Clin Psychiatry; 2007 Nov; 68(11):1793-8. PubMed ID: 18052574
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.
    Modabbernia A; Heidari P; Soleimani R; Sobhani A; Roshan ZA; Taslimi S; Ashrafi M; Modabbernia MJ
    J Psychiatr Res; 2014 Jun; 53():133-40. PubMed ID: 24607293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan.
    Sun L; von Moltke L; Rowland Yeo K
    CPT Pharmacometrics Syst Pharmacol; 2020 Feb; 9(2):106-114. PubMed ID: 31919994
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.
    Kryzhanovskaya LA; Xu W; Millen BA; Acharya N; Jen KY; Osuntokun O
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):157-65. PubMed ID: 22372514
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.
    Kelly DL; Conley RR; Love RC; Morrison JA; McMahon RP
    Ann Clin Psychiatry; 2008; 20(2):71-8. PubMed ID: 18568578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics.
    Kinon BJ; Kollack-Walker S; Jeste D; Gupta S; Chen L; Case M; Chen J; Stauffer V
    J Geriatr Psychiatry Neurol; 2015 Mar; 28(1):67-79. PubMed ID: 25009161
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole.
    Shertzer HG; Kendig EL; Nasrallah HA; Johansson E; Genter MB
    Int J Obes (Lond); 2010 Jun; 34(6):970-9. PubMed ID: 20065957
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Serum IL-1ra, a novel biomarker predicting olanzapine-induced hypercholesterolemia and hyperleptinemia in schizophrenia.
    Lin Y; Peng Y; He S; Xu J; Shi Y; Su Y; Zhu C; Zhang X; Zhou R; Cui D
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Jun; 84(Pt A):71-78. PubMed ID: 29410009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of Combined Therapy of Olanzapine and Samidorphan on Safety and Metabolic Parameters in Schizophrenia Patients: A Meta-Analysis.
    Peng Z; Jia Q; Mao J; Yi Q
    Neuropsychiatr Dis Treat; 2023; 19():2295-2308. PubMed ID: 37908559
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.
    Sun L; Barter Z; von Moltke L; Rowland Yeo K
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1071-1080. PubMed ID: 34185436
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.